The uniquely challenging year of 2020 for all of society proved to be an extraordinary proof-of-concept period for Moderna, even as we have shown that our mRNA-based vaccine can prevent COVID-19, this has encouraged us to pursue more-ambitious development programs within our prophylactic vaccines modality.